France-based D&A Pharma has entered into an exclusive supply, licensing and distribution agreement with Grupo Juste for Alcover, sodium oxybate, a treatment for alcohol dependence.
As part of the deal, Grupo Juste will distribute Alcover in Spain and Central American countries such as Nicaragua, Panama, Costa Rica, Salvador, Honduras, Guatemala, Belize and the Dominican Republic.
Grupo Juste president Inés Juste said: “We are extremely satisfied to announce the arrival of this unique drug as a result of the incredible job that the D&A Pharma team has carried out over the past seven years.”
D&A is also eligible to receive milestone payments and royalties on future sales of Alcover in the designated territory, in addition to the initial upfront payment.
Currently, Alcover is distributed in Italy and Austria.
D&A Pharma president Patrice Debregeas said: “We are very pleased to announce this agreement with Grupo Juste, a pharma company uniquely positioned in Hispanic countries.
“Grupo Juste can draw on its considerable experience to build a powerful franchise in the addiction area and will leverage Alcover’s penetration thanks to its strong local presence and regulatory expertise in Spain and Central America.”
According to the European Medicines Agency’s current evaluation criteria, all the clinical trials carried out in Europe have evaluated the efficacy and safety of sodium oxybate.
